PGIMER nurse wins FICCI recognition for practical cancer-care innovation
Dr Sukhpal Kaur of PGIMER Chandigarh has been honoured with the FICCI Healthcare Excellence Award in the category of Excellence in Nursing Services for public hospitals, a recognition that places nursing-led innovation at the center of cancer care delivery. The award, presented at the 18th FICCI Healthcare Excellence Awards ceremony in New Delhi on October 27, 2026, reflects more than individual achievement. It also draws attention to the growing clinical weight of bedside nursing interventions that are affordable, scalable, and tailored to Indian hospital settings.
Her work is centered on one of the more persistent toxicities in oncology: chemotherapy-induced peripheral neuropathy. This complication can emerge during treatment with neurotoxic chemotherapy and may leave patients with numbness, tingling, pain, functional impairment, and a reduced ability to tolerate ongoing therapy. In practice, neuropathy is not a minor discomfort. It can alter treatment adherence, affect mobility and self-care, and create long-term disability in patients who are already carrying the burden of a cancer diagnosis.
One of Dr Kaur’s key contributions has been the development of indigenous, cost-effective cryotherapy mittens and socks designed to help prevent neuropathy in patients receiving neurotoxic chemotherapy. The logic is straightforward and clinically plausible. Cooling the hands and feet during infusion can reduce blood flow in peripheral tissues and may limit the delivery of neurotoxic agents to vulnerable nerve endings, lowering the risk of injury. In resource-limited settings, the value of such a strategy depends not only on physiologic rationale but also on affordability, comfort, and the ability to use the method repeatedly in routine care.
A single practical intervention can change how nurses think about supportive oncology.
The award recognition places equal emphasis on innovation and affordability, two criteria that often separate laboratory ideas from interventions that can actually be used in crowded public hospitals. Many supportive-care tools sound promising when described in theory, but fail when they require expensive proprietary devices or highly specialized infrastructure. By contrast, indigenous mittens and socks are the kind of intervention that can be adapted to local workflows, applied at the bedside, and offered to patients who might otherwise have no realistic access to preventive supportive care.
Dr Kaur’s role extends beyond device development. Her work also promotes academic excellence, research capacity-building, and the integration of evidence-based practices into clinical nursing. Those elements matter because nursing innovation rarely succeeds in isolation. It depends on training, documentation, quality review, interdisciplinary coordination, and a culture in which nurses are encouraged to observe bedside problems closely enough to redesign care around them. In oncology, where treatment toxicity can be cumulative and unpredictable, nurses often identify the earliest functional changes long before they become visible in a formal medical review.
The recognition from FICCI carries symbolic and operational value for public hospitals. Public-sector institutions frequently manage high patient volumes, variable resources, and a broad mix of socioeconomic need. In that setting, a low-cost preventive intervention has a different kind of clinical importance than it might in a private tertiary center. If the intervention is comfortable for patients, easy to deploy, and inexpensive to reproduce, it can be integrated into care for large numbers of people without widening inequity. That is especially relevant for cancer patients from resource-limited backgrounds, the very population Dr Kaur’s work is intended to serve.
Her award also reflects the broader role of nurses in patient safety and innovation. Nursing services are often the constant thread through a patient’s hospital journey: monitoring symptoms, reinforcing treatment plans, identifying adverse effects, and responding to day-to-day distress that rarely appears in headline outcomes. When nurses lead research or drive practical changes in supportive care, they can influence both immediate symptom control and the long arc of treatment tolerance. In chemotherapy care, preventing neuropathy can preserve function, reduce dose interruptions, and improve a patient’s ability to complete planned therapy.
Public recognition of this work sends a clear message to healthcare systems that practical innovation does not have to be expensive to matter. The value lies in whether a solution reduces harm, fits the realities of bedside care, and can be sustained over time. Indigenous cryotherapy mittens and socks meet that test because they are designed around the needs of patients who may have limited resources but still require protection from a known treatment toxicity.
Dr Kaur expressed gratitude to the PGIMER administration, colleagues, faculty members, nursing professionals, and research team members for their support, and dedicated the recognition to nurses working to improve patient care. The wording fits the way nursing innovation actually happens: through collective effort, shared clinical observation, and persistent attention to the problems that remain untreated in routine practice. The award places that labor in public view, and it places chemotherapy-related neuropathy prevention squarely within the domain of serious clinical nursing work rather than a peripheral supportive measure.
The unresolved question is how widely such nursing-led preventive tools will be adopted across public oncology services, and how quickly hospitals can move from local innovation to routine standard practice.